H Tannenbaum

Summary

Publications

  1. ncbi request reprint An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference
    H Tannenbaum
    Rheumatic Disease Centre of Montreal, Montreal General Hospital McGill University, Montreal, Canada
    Can J Clin Pharmacol 7:4A-16A. 2000
  2. pmc Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib
    H Tannenbaum
    Rheumatic Disease Centre of Montreal, 4060 SteCatherine St West, Suite 740, Montreal H3Z 2Z3 QC, Canada
    Ann Rheum Dis 63:1419-26. 2004
  3. ncbi request reprint Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
    G A W Bruyn
    Medisch Centrum Leeuwarden Zuid, afd Reumatologie, Leeuwarden, 8934 AD, The Netherlands
    Ann Rheum Dis 67:1090-5. 2008

Collaborators

Detail Information

Publications3

  1. ncbi request reprint An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference
    H Tannenbaum
    Rheumatic Disease Centre of Montreal, Montreal General Hospital McGill University, Montreal, Canada
    Can J Clin Pharmacol 7:4A-16A. 2000
    ..The goal of these recommendations is to improve patient outcomes in the primary care setting by maximizing treatment efficacy and minimizing rates of adverse events...
  2. pmc Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib
    H Tannenbaum
    Rheumatic Disease Centre of Montreal, 4060 SteCatherine St West, Suite 740, Montreal H3Z 2Z3 QC, Canada
    Ann Rheum Dis 63:1419-26. 2004
    ..To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis OA in a 13 week, multicentre, randomised, double blind study...
  3. ncbi request reprint Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
    G A W Bruyn
    Medisch Centrum Leeuwarden Zuid, afd Reumatologie, Leeuwarden, 8934 AD, The Netherlands
    Ann Rheum Dis 67:1090-5. 2008
    ..This proof-of-concept study assessed efficacy and safety of everolimus in combination with methotrexate (MTX) in patients with refractory RA...